Program
camizestrant
Also written as “AZD9833”, “Camizestrant” and “AZD9833 with palbociclib”.
Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis · Lymphoma, Follicular, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 189 open or running | phase 3since Dec 23, 2020 | Jul 6, 2018 | Apr 20, 2027phase 3 · NCT05774951 |
Also a collaborator on its studies: icon-plc, quotient-sciences and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Jul 6, 2018.
- Sep 8, 2020Phase 2 study in Breast NeoplasmsNCT04588298 · 135 enrolled · Georgia, Mexico, United Kingdom
- Sep 8, 2020Phase 1 study in Breast NeoplasmsNCT04546347 · 32 enrolled · United Kingdom
- Dec 23, 2020Phase 3 study in Neoplasm MetastasisNCT04711252 · 1,371 enrolled · United States, Austria, Belgium and more
- Mar 24, 2021Phase 1 study in Breast NeoplasmsNCT04818632 · 28 enrolled · China
- Jun 30, 2021Phase 3 study in Neoplasm MetastasisNCT04964934 · 315 enrolled · United States, Australia, Austria and more
- May 4, 20222 phase 1 studies in Breast NeoplasmsNCT05364255, NCT05438303
- Sep 20, 2022Phase 1 study in Breast NeoplasmsNCT05551897 · 14 enrolled · United Kingdom
- Jan 25, 2023Phase 1 study in Lymphoma, FollicularNCT05790304 · 22 enrolled · United States, Bulgaria, Slovakia
- Feb 16, 2023Phase 3 study in Breast NeoplasmsNCT05774951 · 4,300 planned · United States, Argentina, Australia and more
- May 17, 2023Phase 3 study in Breast NeoplasmsNCT05952557 · 5,511 enrolled · United States, Argentina, Australia and more
- Mar 25, 2024Phase 3 study in Advanced Breast CancerNCT06380751 · 788 planned · United States, Argentina, Australia and more
- Aug 7, 2024Phase 1 study in Breast NeoplasmsNCT06547164 · 40 enrolled · United Kingdom
- Feb 16, 2026Phase 2 study in Advanced Breast CancerNCT07427394 · 24 planned · United States, United Kingdom
- May 12, 2026Phase 3 study in Neoplasm MetastasisNCT07647328 · 150 planned · United States, France, Germany and more
Ahead
- Apr 20, 2027Primary completion: phase 3 study in Breast NeoplasmsNCT05774951
- Dec 28, 2027Primary completion: phase 2 study in Advanced Breast CancerNCT07427394
- Feb 28, 2029Primary completion: phase 3 study in Neoplasm MetastasisNCT07647328
- Dec 18, 2029Primary completion: phase 3 study in Advanced Breast CancerNCT06380751
TargetBeta
“An orally available selective estrogen receptor degrader (SERD), ”NCIt, by rule
“Estrogen receptor alpha degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| giredestrant | Hoffmann-La Roche | phase 3 | 17 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 18 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07647328Neoplasm Metastasis · United States, France, Germany and more | 3 | Recruiting | Feb 28, 2029 | 150 |
| NCT07427394Advanced Breast Cancer · United States, United Kingdom | 2 | Recruiting | Dec 28, 2027 | 24 |
| NCT06547164Breast Neoplasms · United Kingdom | 1 | Completed | Aug 20, 2025 | 40 |
| NCT06380751Advanced Breast Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 788 |
| NCT05952557Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 4, 2030 | 5,511 |
| NCT05774951Breast Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Apr 20, 2027 | 4,300 |
| NCT05790304Lymphoma, Follicular · United States, Bulgaria, Slovakia | 1 | Completed | Feb 22, 2024 | 22 |
| NCT05551897Breast Neoplasms · United Kingdom | 1 | Completed | Dec 28, 2022 | 14 |
| NCT05438303Breast Neoplasms · United States | 1 | Completed | Dec 13, 2022 | 59 |
| NCT05364255Breast Neoplasms · United Kingdom | 1 | Completed | Jun 20, 2022 | 6 |
| NCT04964934Neoplasm Metastasis · United States, Australia, Austria and more | 3 | Active, not recruiting | Jun 30, 2025 | 315 |
| NCT04818632Breast Neoplasms · China | 1 | Completed | Sep 7, 2023 | 28 |
| NCT04711252Neoplasm Metastasis · United States, Austria, Belgium and more | 3 | Active, not recruiting | Jun 26, 2026 | 1,371 |
| NCT04588298Breast Neoplasms · Georgia, Mexico, United Kingdom | 2 | Completed | Jun 19, 2023 | 135 |
| NCT04546347Breast Neoplasms · United Kingdom | 1 | Completed | Jan 7, 2021 | 32 |
| NCT04541433Breast Neoplasms · Japan | 1 | Completed | Jul 29, 2022 | 10 |
| NCT04214288Neoplasm Metastasis · United States, Belgium, Canada and more | 2 | Active, not recruiting | Aug 30, 2022 | 240 |
| NCT03616587Breast Neoplasms · United States, Spain, United Kingdom | 1 | Active, not recruiting | Sep 16, 2024 | 396 |
How it is read
Names in the registry
- “AZD9833”, 10 entries
- “Camizestrant”, 8 entries
- “AZD9833 with palbociclib”, 3 entries
- “AZD9833 with everolimus”, 3 entries
- “AZD9833 with abemaciclib”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 13 studies
- Neoplasm Metastasis, 4 studies
- Lymphoma, Follicular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.